Chronic Granulomatous Disease Plasma
About: Chronic Granulomatous Disease Plasma samples are collected from donors diagnosed with chronic granulomatous disease (CGD). Suitable for profiling inflammatory cytokines, oxidative stress markers, and soluble immune mediators linked to infection susceptibility and granuloma formation.
Chronic Granulomatous Disease Plasma | High-Quality Human Plasma from Chronic Granulomatous Disease Donors
Chronic Granulomatous Disease Plasma is collected from donors clinically diagnosed with Chronic Granulomatous Disease (CGD) and processed within hours of collection to preserve key analytes such as cytokines, proteins, and metabolites. This human plasma supports research focused on inflammatory pathways, immune profiling, and biomarker discovery in chronic granulomatous disease pathophysiology.
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed CGD donors
- Processed within one day of collection
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
De-identified Donor Data
- Verified CGD diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Additional chronic granulomatous disease-specific metadata available
Applications
- Biomarker discovery and validation
- Cytokine and inflammation profiling
- Metabolomics and proteomics studies
- Therapeutic response research
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering and Customization
Chronic Granulomatous Disease plasma is available in standard and custom volumes. For international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – with the exception of GMP leukopaks, all our products are research use only (RUO).
1 Answer
Our complete catalog can be found here: https://sanguinebio.com/products/
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective colleciton services to tailored to fit your research. For more information and request a quote, please see: https://sanguinebio.com/prospective-biospecimen-collection-services/
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory which can be found here https://sanguinebio.com/products/?pro_inventory=inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: https://sanguinebio.com/quality-and-compliance/
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.